Two Abstracts on *Nanvuranlat* Accepted for ASCO GI 2027

― Featuring the Global Phase III Clinical Trial "Beacon-BTC" and an Investigator-Initiated Clinical Trial in Japan ―

November 16, 2026

J-Pharma Co., Ltd.

President and CEO: Masuhiro Yoshitake

Securities Code: 520A

J-Pharma Co., Ltd. (Head Office: Minato-ku, Tokyo; President and CEO: Masuhiro Yoshitake; hereinafter "the Company") announces that two abstracts concerning *nanvuranlat* (development code: JPH203), a LAT1 inhibitor under development by the Company, have been accepted for the 2027 ASCO Gastrointestinal Cancers Symposium (hereinafter "ASCO GI 2027"), to be held in San Francisco, United States, from January 21 to 23, 2027.

The two accepted abstracts cover the following clinical trials in biliary tract cancer:

• Global Phase III Clinical Trial "Beacon-BTC"

A global clinical trial conducted by J-Pharma to evaluate the efficacy and safety of *nanvuranlat* as a second-line treatment for biliary tract cancer.

• Investigator-Initiated Clinical Trial "JON2404-B"

An investigator-initiated clinical trial led by the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. The trial primarily evaluates the safety and tolerability of *nanvuranlat* alone and in combination with immune checkpoint inhibitors. It also explores the efficacy of the combination therapy.

The Company will provide further details, including the official abstract titles and presentation information, once ASCO releases the official announcements.

J-Pharma will continue to advance the development of *nanvuranlat*, with the goal of providing new treatment options for patients with biliary tract cancer.

ASCO GI 2027 Event Details

Event: 2027 ASCO Gastrointestinal Cancers Symposium

Dates: January 21–23, 2027

Location: San Francisco, California, USA

Official Website: https://www.asco.org/gi

Related Information

・Global Phase III Clinical Trial “Beacon-BTC” for Biliary Tract Cancer

https://www.j-pharma.com/en/clinical_trial/biliary_tract_cancer_p3/

・Investigator-Initiated Clinical Trial “JON2404-B” for Biliary Tract Cancer

https://www.j-pharma.com/en/clinical_trial/biliary_tract_cancer_p1/

About J-Pharma Co., Ltd.

J-Pharma Co., Ltd. aims to pursue new possibilities for SLC transporters and contribute to the hope and health of people worldwide through the development of innovative new drugs that address unmet medical needs. Under this mission, the Company has focused on LAT1 (L-type amino acid transporter 1), one of the SLC transporters discovered by the Company’s founder, and is advancing the development of LAT1 inhibitors to address the needs of patients with cancer and autoimmune diseases, where existing drugs are insufficient.

For more information, please visit:

https://www.j-pharma.com/en/

Inquiries:

J-Pharma Co., Ltd.

Planning Department

TEL: +81-3-6432-4270

https://www.j-pharma.com/en/contact